{"id":56996,"date":"2026-02-12T21:53:16","date_gmt":"2026-02-12T13:53:16","guid":{"rendered":"https:\/\/flcube.com\/?p=56996"},"modified":"2026-02-12T21:53:17","modified_gmt":"2026-02-12T13:53:17","slug":"novo-nordisk-to-launch-wegovy-vial-version-in-price-war-with-eli-lilly","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56996","title":{"rendered":"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly"},"content":{"rendered":"\n

Novo Nordisk A\/S<\/strong> (NYSE:\u202fNVO<\/a><\/strong>) announced plans to launch a vial version of Wegovy (semaglutide)<\/strong>, shifting from its current injector pen-only format<\/strong> to compete with Eli Lilly’s<\/strong> (NYSE:\u202fLLY<\/a><\/strong>) lower-priced Zepbound vials<\/strong> and alleviate supply constraints<\/strong>. The Danish pharmaceutical giant is aggressively cutting prices<\/strong>\u2014offering Wegovy oral tablets at USD\u202f149 per month<\/strong>\u2014a strategy expected to reduce 2026 sales by up to 13%<\/strong> as it battles to regain obesity market share<\/strong> amid intensifying GLP-1 competition<\/strong>.<\/p>\n\n\n\n

Strategic Initiative Overview<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Company<\/strong><\/td>Novo Nordisk A\/S (NYSE:\u202fNVO)<\/td><\/tr>
Product<\/strong><\/td>Wegovy (semaglutide 2.4mg) \u2013 GLP-1 receptor agonist<\/td><\/tr>
Current Format<\/strong><\/td>Pre-filled injector pen only<\/td><\/tr>
New Format<\/strong><\/td>Vial version<\/strong> (multi-dose, patient-administered)<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Wegovy oral tablets: USD\u202f149\/month<\/strong> direct-to-consumer<\/td><\/tr>
Financial Impact<\/strong><\/td>Up to 13% sales reduction<\/strong> in 2026<\/td><\/tr>
Competitive Response<\/strong><\/td>Counter Eli Lilly Zepbound vials<\/strong> launched ~2 years ago<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Competitive Dynamics<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
GLP-1 Supply Constraints<\/strong><\/td>Wegovy and Ozempic shortages (2023-2024)<\/strong> created gray market<\/strong> and compounding pharmacy exploitation<\/strong>; vial format simplifies manufacturing<\/strong> and expands capacity<\/strong><\/td><\/tr>
Eli Lilly First-Mover Advantage<\/strong><\/td>Zepbound vials launched ~2024<\/strong> at lower price point<\/strong>; captured price-sensitive patients<\/strong> and commercial formulary preference<\/strong>; Novo playing catch-up<\/strong><\/td><\/tr>
Price War Escalation<\/strong><\/td>USD\u202f149\/month Wegovy tablets<\/strong> vs. Zepbound vial pricing<\/strong>; margin compression<\/strong> inevitable but volume growth<\/strong> prioritized to defend market leadership<\/strong><\/td><\/tr>
Patient Access Expansion<\/strong><\/td>Lower-cost options<\/strong> address insurance coverage gaps<\/strong> and cash-pay patients<\/strong>; counter FDA compounding crackdown<\/strong> by legitimate supply expansion<\/strong><\/td><\/tr>
Revenue Trade-off<\/strong><\/td>13% sales decline projection<\/strong> reflects strategic sacrifice of near-term revenue<\/strong> for long-term market share defense<\/strong> against tirzepatide dual GIP\/GLP-1 efficacy advantage<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Format Comparison<\/h2>\n\n\n\n
Format<\/th>Novo Nordisk Wegovy<\/th>Eli Lilly Zepbound<\/th>Strategic Implication<\/th><\/tr><\/thead>
Injector Pen<\/strong><\/td>Current standard<\/strong>; premium pricing<\/td>Autoinjector available<\/td>Convenience premium<\/strong>; higher margins<\/strong><\/td><\/tr>
Vial<\/strong><\/td>New launch 2026<\/strong><\/td>Launched ~2024<\/strong><\/td>Cost reduction<\/strong>; supply flexibility<\/strong>; price competition<\/strong><\/td><\/tr>
Oral Tablet<\/strong><\/td>USD\u202f149\/month direct-to-consumer<\/strong><\/td>Not available<\/td>Maximum accessibility<\/strong>; lowest price point<\/strong>; volume driver<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Financial & Strategic Outlook<\/h2>\n\n\n\n
Priority<\/th>Execution Plan<\/th>Timeline<\/th><\/tr><\/thead>
Vial Launch<\/strong><\/td>Manufacturing scale-up; regulatory filings (US, EU, China)<\/td>2026<\/td><\/tr>
Pricing Optimization<\/strong><\/td>Balance volume growth<\/strong> vs. margin preservation<\/strong>; formulary negotiations<\/strong><\/td>Ongoing<\/td><\/tr>
Supply Assurance<\/strong><\/td>Vial format<\/strong> alleviates pen device manufacturing bottlenecks<\/strong><\/td>2026-2027<\/td><\/tr>
Market Share Defense<\/strong><\/td>Retain leadership<\/strong> vs. Zepbound<\/strong>; prepare for oral GLP-1 competition<\/strong> (orforglipron, etc.)<\/td>2026-2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Wegovy vial launch timelines, pricing strategy effectiveness, and Novo Nordisk’s obesity market share trajectory. Actual results may differ due to manufacturing scale-up challenges, competitive responses from Eli Lilly, and payer reimbursement dynamics for lower-cost GLP-1 formats.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Novo Nordisk A\/S (NYSE:\u202fNVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting…<\/p>\n","protected":false},"author":1,"featured_media":56997,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[199,4445,148,911,860],"class_list":["post-56996","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-eli-lilly","tag-metabolic-disease","tag-novo-nordisk","tag-nyse-lly","tag-nyse-nvo"],"yoast_head":"\nNovo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE:\u202fNVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting from its current injector pen-only format to compete with Eli Lilly's (NYSE:\u202fLLY) lower-priced Zepbound vials and alleviate supply constraints. The Danish pharmaceutical giant is aggressively cutting prices\u2014offering Wegovy oral tablets at USD\u202f149 per month\u2014a strategy expected to reduce 2026 sales by up to 13% as it battles to regain obesity market share amid intensifying GLP-1 competition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56996\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE:\u202fNVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting from its current injector pen-only format to compete with Eli Lilly's (NYSE:\u202fLLY) lower-priced Zepbound vials and alleviate supply constraints. The Danish pharmaceutical giant is aggressively cutting prices\u2014offering Wegovy oral tablets at USD\u202f149 per month\u2014a strategy expected to reduce 2026 sales by up to 13% as it battles to regain obesity market share amid intensifying GLP-1 competition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56996\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-12T13:53:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-12T13:53:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1205.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly\",\"datePublished\":\"2026-02-12T13:53:16+00:00\",\"dateModified\":\"2026-02-12T13:53:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996\"},\"wordCount\":412,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1205.webp\",\"keywords\":[\"Eli Lilly\",\"Metabolic disease\",\"Novo Nordisk\",\"NYSE: LLY\",\"NYSE: NVO\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56996#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56996\",\"name\":\"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1205.webp\",\"datePublished\":\"2026-02-12T13:53:16+00:00\",\"dateModified\":\"2026-02-12T13:53:17+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE:\u202fNVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting from its current injector pen-only format to compete with Eli Lilly's (NYSE:\u202fLLY) lower-priced Zepbound vials and alleviate supply constraints. The Danish pharmaceutical giant is aggressively cutting prices\u2014offering Wegovy oral tablets at USD\u202f149 per month\u2014a strategy expected to reduce 2026 sales by up to 13% as it battles to regain obesity market share amid intensifying GLP-1 competition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56996\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1205.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/1205.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lill\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56996#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly - Insight, China's Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE:\u202fNVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting from its current injector pen-only format to compete with Eli Lilly's (NYSE:\u202fLLY) lower-priced Zepbound vials and alleviate supply constraints. The Danish pharmaceutical giant is aggressively cutting prices\u2014offering Wegovy oral tablets at USD\u202f149 per month\u2014a strategy expected to reduce 2026 sales by up to 13% as it battles to regain obesity market share amid intensifying GLP-1 competition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56996","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly","og_description":"Novo Nordisk A\/S (NYSE:\u202fNVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting from its current injector pen-only format to compete with Eli Lilly's (NYSE:\u202fLLY) lower-priced Zepbound vials and alleviate supply constraints. The Danish pharmaceutical giant is aggressively cutting prices\u2014offering Wegovy oral tablets at USD\u202f149 per month\u2014a strategy expected to reduce 2026 sales by up to 13% as it battles to regain obesity market share amid intensifying GLP-1 competition.","og_url":"https:\/\/flcube.com\/?p=56996","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-12T13:53:16+00:00","article_modified_time":"2026-02-12T13:53:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1205.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56996#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56996"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly","datePublished":"2026-02-12T13:53:16+00:00","dateModified":"2026-02-12T13:53:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56996"},"wordCount":412,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56996#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1205.webp","keywords":["Eli Lilly","Metabolic disease","Novo Nordisk","NYSE: LLY","NYSE: NVO"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56996#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56996","url":"https:\/\/flcube.com\/?p=56996","name":"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56996#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56996#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1205.webp","datePublished":"2026-02-12T13:53:16+00:00","dateModified":"2026-02-12T13:53:17+00:00","description":"Novo Nordisk A\/S (NYSE:\u202fNVO) announced plans to launch a vial version of Wegovy (semaglutide), shifting from its current injector pen-only format to compete with Eli Lilly's (NYSE:\u202fLLY) lower-priced Zepbound vials and alleviate supply constraints. The Danish pharmaceutical giant is aggressively cutting prices\u2014offering Wegovy oral tablets at USD\u202f149 per month\u2014a strategy expected to reduce 2026 sales by up to 13% as it battles to regain obesity market share amid intensifying GLP-1 competition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56996#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56996"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56996#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1205.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1205.webp","width":1080,"height":608,"caption":"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lill"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56996#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk to Launch Wegovy Vial Version in Price War with Eli Lilly"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/1205.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56996"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56996\/revisions"}],"predecessor-version":[{"id":56998,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56996\/revisions\/56998"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56997"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}